The online healthcare newspaper Con Salud has interviewed our research associate, Dr. Senthil Muthuswamy, Director of Translational Research at the Beth Israel Deaconess Hospital Cancer Center in Boston, and published in detail what the platform consists of.
opT of the Peaches Group
In the article, Senthil explains how this project will build on the Harvard patent that Peaches Biotech acquired a few months ago for a treatment that aims to cure pancreatic cancer, one of the deadliest cancers in existence.
Breakthrough in cancer research
The research, together with Dr. Manuel Hidalgo, chief of the Division of Hematology-Oncology at Weill Cornell Medicine and New York Presbyterian Hospital in New York, will identify and target tumor cells of the pancreas and other solid tumors such as colon or gastrointestinal secretory tumors. This is a major breakthrough in cancer research as it is the first time we can use the patient’s tumor cells to selectively amplify cytotoxic T cells with selectivity to kill tumor cells.
Dr. Muthuswamy also shares in the publication how the platform is applicable for all gastrointestinal cancers (e.g., colon, stomach, gastric, etc.), as well as for treating breast cancer patients.
You can read the full interview in Con Salud.
(Photo credit cover image: BIDMC)